AstraZeneca waxay heshaa kor u qaadida sharciyeynta ee daawooyinka kansarka

kansarka-unugga

AstraZeneca waxay heshay labanlaab kor u qaadis ah faylalka Oncology Talaadadii, ka dib markii sharciyeeyayaasha Mareykanka iyo Yurub ay aqbaleen soo gudbinta sharciyeynta dawooyinkeeda, tallaabada ugu horreysa ee lagu guuleysto oggolaanshaha daawooyinkan.

Daawo-sameeyaha Anglo-Swedish, iyo MedImmune, cududdeeda cilmi-baarista iyo horumarinta cilmiga bayoolajiga caalamiga ah, ayaa ku dhawaaqday in Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA) ay aqbashay codsiga shatiga ee moxetumomab pasudotox, oo ah daawo cusub oo suurtagal ah oo loogu talagalay daaweynta bukaanka qaangaarka ah ee leh unug timo leh. leukemia (HCL) kuwaas oo helay ugu yaraan laba sadar oo hore oo daaweyn ah.

FDA waxay ku abaalmarisay heerka "dib u eegista mudnaanta" dawada, taasoo la siiyay dawooyinka, haddii la ogolaado, bixin doona horumar la taaban karo ee daaweynta, ogaanshaha, ama ka hortagga xaaladaha halista ah. Go’aan ayaa la filayaa rubuci saddexaad ee sanadkan.

Dhanka kale, Hay'adda Daawooyinka Yurub waxay aqbashay soo gudbinta sharciyeynta Lynparza, daawada ay AstraZeneca hadda la wadaagto 50:50 shuraako la ah Merck, shirkadda daroogada ee Maraykanka, si loogu daweeyo kansarka naasaha ee ku faafa meelo kale oo jirka ah bukaanada qaba gaar ah. isu beddelka hidde.

Haddii la oggolaado, daawadu waxay noqon doontaa joojiyaha PARP ee ugu horreeya ee daaweynta kansarka naasaha ee Yurub. PARP waa borotiin laga helo unugyada bini'aadamka kaas oo ka caawiya unugyadaas inay is hagaajiyaan marka ay dhaawacmaan. Joojinta habka dayactirka ee unugyada kansarka, PARP inhibitors waxay caawiyaan unugga inuu dhinto.

Lynparza bishii Jannaayo waxay noqotay kahortagayaasha PARP ee u ansixiyay meel kasta oo adduunka ka mid ah kansarka naasaha, markii ay ku guuleysatay hor-u-socodka maamulayaasha Mareykanka.

Tijaabooyinkii ugu dambeeyay, Lynparza waxay si wayn u dheeraysay badbaadada horumar la'aanta ah marka la barbar dhigo kiimoterabiga waxayna hoos u dhigtay halista horumarka ama dhimashada boqolkiiba 42.

Sannadka 2017 shan meelood meel iibinta alaabta Astra waxay ka yimaaddeen oncology shirkadduna waxay filaysaa in saamigani kor u kaco. Saamiyada kooxda ayaa xidhay 0.6 boqolkiiba £49.26.

Horumar gaar ah, Compugen, oo ah shirkad farmashiye oo Israa'iil ah, ayaa sheegtay in ay heshiis shati gaar ah la gashay MedImmune kaas oo awood u siinaya horumarinta alaabada ka hortagga unugyada si loo daaweeyo kansarka.

MedImmune waxay xaq u leedahay inay abuurto badeecooyin badan oo hoos yimaada shatiga "waxayna mas'uul ka noqon doontaa dhammaan cilmi-baarista, horumarinta iyo hawlaha ganacsiga ee hoos yimaada heshiiska", ayuu yiri Compugen.

Shirkadda Israa'iil waxay heli doontaa $10m oo horudhac ah waxayna xaq u leedahay inay hesho ilaa $200m oo ah horumarinta, sharciyeynta iyo ganacsiga ee badeecadda ugu horreysa, iyo sidoo kale royalties iibka alaabta mustaqbalka.

Anat Cohen-Dayag, madaxa fulinta Compugen, ayaa sheegay in heshiiska "wuxuu noo ogolaanayaa inaan lacag ka samayno horumarka sayniska ee gaarka ah ee barnaamijyadeena, inta aan sii wadeyno horumarinta barnaamijyadayada hogaaminta ee tijaabooyinka caafimaadka".


Waqtiga boostada: Apr-23-2018
;
WhatsApp Online chat!